- Global Pharma News & Resources

VeriSIM Life Appoints Dr. Szczepan Baran as New Chief Scientific Officer   

  • As Chief Scientific Officer, Szczepan Baran will lead the research and partnership development strategy to promote the efficiency, profitability and competitive position of VeriSIM Life
  • He previously served as head of Global Emerging Technologies within Comparative Medicine at Novartis Institute for Biomedical Research (NIBR)

SAN FRANCISCO--(BUSINESS WIRE)--VeriSIM Life (VeriSIM), the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, today announced the appointment of Szczepan Baran, VMD, MS as Chief Scientific Officer. Dr. Baran will set the research and development strategy of the company and oversee scientific functions, including basic and applied research projects, and develop new processes, technologies and products. Dr. Baran will report directly to Dr. Jo Varshney, Chief Executive Officer of VeriSIM.

“In Dr. Baran, we’re gaining more than a scientific leader; we’re getting someone who is passionate about what we’re trying to accomplish, a strategic thought partner who is not afraid to roll up his sleeves and a phenomenal culture fit,” said Dr. Jo Varshney, founder and CEO of VeriSIM Life. “Dr. Baran's reputation in our industry is a highly valuable addition to our growing company, and I know he will thrive in his new role with us. I also look forward to him driving innovation through his deep understanding of our BIOiSIM platform and its creative application in the translational length and breadth of drug development.”

Dr. Baran joins VeriSIM from Novartis Institute for Biomedical Research (NIBR) where he was head of Global Emerging Technologies. In this position, he led an integrated digital enterprise strategy focusing on the development and incorporation of patient-relevant AI technologies. In addition, Dr. Baran uncovered new scientific insights, generate scientific breakthroughs and collect more physiologically and clinically relevant data and digital endpoints to optimize reproducibility and clinical translation. This included guiding the strategy in seeking high-impact scientific problems and collaborators where these emerging and disruptive technologies could uniquely aid scientific research.

Dr. Baran is a graduate of the University of Delaware and the University of Pennsylvania School of Veterinary Medicine. He has an extensive record of both peer-reviewed publications and conference presentations.

VeriSIM’s BIOiSIM platform, driven by artificial intelligence (AI) and machine learning (ML), de-risks R&D decisions by providing meaningful insights much earlier in the drug development process with unprecedented accuracy and scalability. VeriSIM’s platform solves a translatability problem within the drug development phase and ensures clinical success of drugs intended for highly unmet needs.

“We look forward to Dr. Baran directing the development of VeriSIM’s annual scientific goals, obtaining and acting upon inputs from the Board of Directors, the Scientific Advisory Committee, collaborators and relevant stakeholders,” said Dr. Varshney. “He will also supervise all scientific projects and operations to guarantee that the organization meets its scientific milestones.”

Dr. Jo Varshney, DVM and PhD, founded VeriSIM Life in 2017 alongside a cross-functional team of pharmaceutical scientists, software engineers and AI/ML and simulation experts.

For more information about VeriSIM Life follow them on Twitter at @VeriSIMlife, visit or email

About VeriSIM Life

VeriSIM Life has developed a sophisticated computational platform that leverages advanced AI and ML techniques to improve drug discovery and development by greatly reducing the time and money it takes to bring a drug to market. BIOiSIM is a first-in-class 'virtual drug development engine' that offers unprecedented value for the drug development industry by narrowing down the number of drug compounds that offer anticipated value for the treatment or cure of specific illnesses or diseases. The program not only reduces the time and cost of drug discovery and development, it also greatly reduces the need for animal testing that, in the vast majority of cases, does not translate to humans (over 90% of drugs tested in animals fail to pass human clinical trials). For more information visit:


Media Contact:
Dwain Schenck
M: 203-223-5230

Senior Director Business Development
Nilesh Gupta
M: 415-991-3783

Editor Details

  • Company:
    • Businesswire
Last Updated: 10-Mar-2022